Synageva BioPharma announces dosing of patients commenced with SBC-103 in Phase 1/2 Study for MPS IIIB and FDA Fast Track Designation Granted

Synageva BioPharma announced that dosing with SBC-103 in patients with MPS IIIB has begun as part of a Phase 1/2 study, and the FDA recently granted SBC-103 Fast Track designation. Fast Track is a process designed to facilitate development and expedite review of drugs to treat serious and life-threatening conditions and fill an unmet medical need to get important new drugs to patients expeditiously. Read the full press release here.

This entry was posted in News. Bookmark the permalink.

Comments are closed.